Welcome to BioSeeker Group!

Triple Analysis: Leukemia, Melanoma and Pancreatic Cancer

Additional Information

Published Date Jun 12, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3431
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Leukemia, Melanoma and Pancreatic Cancer in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in Leukemia, Melanoma and Pancreatic Cancer.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Melanoma and Pancreatic Cancer.

    To find out more about Triple Analysis: Leukemia, Melanoma and Pancreatic Cancer, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Melanoma and Pancreatic Cancer is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in Leukemia, Melanoma and Pancreatic Cancer. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Leukemia
The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and and eight subindications of leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part II: Melanoma
The melanoma drug report part comprises defined and up to date development strategies for 282 drugs within the portfolio of 164 companies world-wide, from Ceased to Marketed. The report extensively analyses their 226 identified drug targets, organized into 187 drug target strategies, and assesses them in melanoma.
This part is based on the following publication:
Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?

Part III: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 investigators, from Ceased to Marketed. This part extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in eight different compound strategies.
This part is based on the following publication:
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Leukemia
5.1 The Scope of this Report 29
6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443
7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727
8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728
9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129
11 Disclaimer 1130
12 Drug Index 1131
13 Company Index 1140
Figures: Includes 6 Figures
Tables: Includes 253 Tables
Total Number of Pages: 1,147

Part II: Melanoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Melanoma Drugs for the Highest Therapeutic Outcome and Return on Investment (226 Drug Targets) 30-467
7 First-in-Class and Me-too Analysis of Melanoma Drugs (187 Drug Target Strategies and 282 Drugs) 468-677
8 Is First-in-Class the Best-in-Class? 488-678
9 Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs by Compound Strategy (7 Compound Strategies) 679-710
10 The Competition Through Close Mechanistic Approximation of Melanoma Drugs 711
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Melanoma Drug Pipeline by Company (164 Companies and 282 Drugs) 716-1165
12 Disclaimer 1166
Figures: Includes 5 Figures
Tables: Includes 222 Tables
Total Number of Pages: 1,181

Part III: Pancreatic Cancer
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (197 Drug Targets) 31-422
7 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development (163 Drug Target Strategies and 247 Drugs) 423-612
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Compound Strategies) 613-651
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator (158 Investigators and 247 Drugs) 652-1088
10 Drug Index 1091
11 Company Index 1098
Figures: Includes 7 Figures
Tables: Includes 218 Tables
Total Number of Pages: 1,103

This Report Includes the Following Companies:
3M Pharmaceuticals
3SBio
4SC
AB Science
Abbott
AbbVie
Abiogen
Actelion
Actinium Pharmaceuticals
Active Biotech
Adherex
Advanced Life Sciences
Advantagene
Advaxis
AEgera
Agenus
Aida Pharmaceuticals
Alexion
Alfa Wassermann
Alnylam
AlphaVax
Altor BioScience
Ambit Biosciences
Amgen
AngioChem
Antisense Pharma
Antisoma
Anza Therapeutics
Aphios
Apogee Biotechnology
ApopLogic Pharmaceuticals
Apotex
Arca biopharma
Ardea Biosciences
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Asahi Kasei Pharma
Ascenta Therapeutics
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Bayer
Betapharma
Bio-Medisinsk Innovasjon
Bio-Path Holdings
BioAlliance Pharma
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
Biokine Therapeutics
Bionovo
BioNTech
BioNumerik
BioSante
Biosceptre
Biotech Ltd
Biotecnol
Bioton
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Callisto Pharmaceuticals
Cancer Advances
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
Choongwae
CJ Corp
Clavis Pharma
CompleGen
Cornerstone Pharmaceuticals
Cosmo Pharmaceuticals
CritiTech
CSL
Curacyte
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokinetics
CytRx
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
DiaMedica
DNAVEC
Dong-A
EGEN Inc
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Epizyme
Erimos
Esperance Pharmaceuticals
Exelixis
ExonHit Therapeutics
FibroGen
Flamel Technologies
Galectin Therapeutics
Gemin X Biotechnologies
Genencor
Genentech
Genmab
Genta
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
GlycoMimetics
Gradalis
Hanmi
Hayashibara
Heber Biotec
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Ichor Medical Systems
Idera Pharmaceuticals
IDM Pharma
IkerChem
ImClone Systems
Immune Pharmaceuticals
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
Immunovaccine
ImmuPharma
Immutep
Incyte Corporation
InDex Pharmaceuticals
Inex
Infinity Pharmaceuticals
Innate Pharma
Innovive
Inotek
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Intrexon
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
Italfarmaco
Jennerex Biotherapeutics
Johnson & Johnson
Kadmon
KAEL-GemVax
KaloBios
Kalypsys
Kanisa
Karyon-CTT
Kiadis
Kinex
Kyowa Hakko Kirin
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lipotek
Lorus Therapeutics
Mannkind
MAT Biopharma
MaxCyte
MaxoCore Pharmaceuticals
MBiotec
Meda
MediGene
Medisyn Technologies
Memgen
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Mochida
Mojave Therapeutics
MolMed
Mologen
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
NIH
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Novacea
NovaLead
Novartis
Novogen
Oasmia
Oncalis
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Oncozyme Pharma
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
OXiGENE
Pacific Biotech
Paladin Labs
PanaGin
Patrys
PBL Therapeutics
Pepscan Therapeutics
Pfizer
Pharmacyclics
PharmaMar
Pharmexa
PhiloGene
PIERIS Proteolab
Pierre Fabre
Piramal
Portola Pharmaceuticals
Prochon Biotech
Progen
ProMetic Life Sciences
Protgen
Ras Therapeutics
Reata Pharmaceuticals
Regeneron
Regulon
Reliance Life Sciences
RESprotect
Rexahn
Rigel
Rottapharm Madaus
Samyang
Sangamo BioSciences
Sanofi
Sanofi-Aventis
Santaris Pharma
Santhera Pharmaceuticals
Sareum
SBI Biotech
SBIO
Scancell
Seattle Genetics
Semafore Pharmaceuticals
Sepal Pharma
Servier
Shenogen
Shire
Sidus
Simcere Pharmaceuticals
Solbec Pharmaceuticals
Southern Research Institute
Spirogen
Stemline Therapeutics
Sunesis
SuperGen
Swedish Orphan Biovitrum
SymBio Pharmaceuticals
Symbiotec
Synageva BioPharma
Synta Pharmaceuticals
Syntrix
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Targa Therapeutics
TargeGen
Targepeutics
Tau Therapeutics
TeGenero
Teva
Thallion Pharmaceuticals
Therion Biologics
Titan Pharmaceuticals
to-BBB
Tolerx
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
Trion Pharma
UMN Pharma
Valeant
VaxOnco
VBL Therapeutics
Vectura
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
ViroMed
WntResearch
XBiotech
Xencor
Xerion
Yakult Honsha
Yamasa Corporation
YM BioSciences
York Pharma
Zenyaku Kogyo
Zeria
A Shortlist of Drugs Included are:
AEB071
AEG-35156
aflibercept
agatolimod
AGS-1C4D4
aldesleukin
alemtuzumab
ALT-801
amonafide malate
amsacrine
APO-866
apricoxib
ARC-100
ARQ-197
ARRY-438162
astuprotimut-r
Auto TAG vaccine
axitinib
barasertib
bardoxolone methyl
belinostat
bevacizumab
bisantrene
BMS-663513
BMS-936558
bortezomib
bosutinib
brivanib alaninate
brivudine
Buparlisib
Cabozantinib
capecitabine
catumaxomab
CB-10-01
celecoxib
cetuximab
CG-201
cilengitide
cixutumumab
cladribine
clofarabine
conatumumab
cositecan
CPI-613
CRLX-101
CSF-GM
CT-011
cytarabine ocfosfate
cytarabine, injectable
dalotuzumab
dasatinib
daunorubicin
decitabine
denenicokin
denileukin diftitox
dinaciclib
docetaxel
dovitinib lactate
doxorubicin
E-7820
E7449
elacytarabine
EMD-273063
endostatin
eniluracil
enocitabine
entinostat
enzastaurin hydrochloride
epirubicin
erlotinib
everolimus
Exherin
fresolimumab
ganetespib
ganitumab
gefitinib
gemtuzumab ozogamicin
glembatumumab vedotin
golvatinib
GSK-1120212
GSK-2118436
GV-1001
GVAX
Hi-8 MEL
histamine dihydrochloride
icotinib hydrochloride
idarubicin
imatinib mesilate
IMP-321
INCB-24360
interferon
interferon (alpha-N1)
interferon (alpha)
interferon (alpha2)
interferon (alpha2a)
interferon (alpha2b)
interferon (alpha2c)
interferon (gamma)
interferon alpha-2b
interleukin-12
interleukin-2
intetumumab
IPH-1101
ipilimumab
irinotecan
irinotecan hydrochloride
ispinesib mesylate
JX-594
kahalalide F
KD032
L19-IL2
Lambrolizumab
lapatinib ditosylate
LEE-011
lenvatinib
lestaurtinib
leukemia vaccine
LGX818
LipoVIL12
lumiliximab
masitinib
MDX-1379
MetXia
MGN-1601
midostaurin
mitoxantrone
MKC-1
MKC-1106-MT
mocetinostat
MORAb-004
motexafin gadolinium
nadroparin
nilotinib
nimotuzumab
obinutuzumab
oblimersen sodium
ofatumumab
olaparib
ON-01910
OncoVAX
OTS-102
P-276-00
P276-00
paclitaxel
PancAtak
panobinostat
pasireotide
pasireotide LAR
pazopanib hydrochloride
PCI-27483
peginterferon alfa-2b
pemetrexed disodium
pentamidine isethionate
pentostatin
perifosine
pimasertib
plitidepsin
poly-ICLC
PX-12
RAF-265
ramucirumab
razoxane
retaspimycin
Rexin-G
rhIFN-alpha
ridaforolimus
rintatolimod
rituximab
romidepsin
RX-0201
sagopilone
sargramostim
SCIB-1
selumetinib
siltuximab
sobuzoxane
sorafenib tosylate
ß-lapachone
sunitinib malate
talminogene laherparepvec
tamibarotene
tegafur + uracil
temsirolimus
teniposide
tesetaxel
thalidomide
thymalfasin
tigatuzumab
tipifarnib
tocilizumab
trabedersen
trastuzumab
tremelimumab
triciribine phosphate
TS-1
tucotuzumab celmoleukin
varlitinib
velimogene aliplasmid
veliparib
vemurafenib
verubulin
vinflunine ditartrate
vismodegib
vitespen
volociximab
vosaroxin
WX-671
YM-155
Z-360
zanolimumab
zorubicin

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Melanoma and Pancreatic Cancer.
    To find out more about Triple Analysis: Leukemia, Melanoma and Pancreatic Cancer, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Melanoma and Pancreatic Cancer is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Leukemia, Lymphoma and Antibodies
This triple analysis focuses on cancer drug development strategies in both Leukemia and Lymphoma and by the compound strategy of Antibodies. Learn More


Triple Analysis: Leukemia, Cancer Vaccines and Peptides
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Peptides). Learn More

Other selected research from the 'Oncology' category:


Antibody Drug Target Atlas in Oncology - Where to Commercialize in a Crowded Market Place?
This report comprises defined and up to date development strategies for 441 antibody drugs (993 projects) within the portfolio of 168 investigators, from Ceased to Marketed. The report extensively analyses 225 identified targets of antibody drugs, organized into 234 drug target profiles, and assesses them in 69 different cancer indications. Learn More


Transcriptional Misregulation in Cancer Drug Pipeline Update
BioSeeker Group have identified 292 companies plus partners who are today developing 350 transcriptional misregulation targeting drugs in 1432 developmental projects in cancer across 229 different targets. In addition, there are 6 suspended drugs and another 204 drugs where development has been ceased. Learn More